Grifols | GRFS - Operating Expenses


Grifols reported EUR1.99B in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Alaunos Therapeutics USD 1.01M 175K Mar/2026
Arca Biopharma USD 36.43M 2M Mar/2026
aTyr Pharma USD 2.42M 83.19M Mar/2026
Bio Path USD 297K 191K Mar/2026
Brainstorm Cell Therapeutics USD 2.05M 198K Mar/2026
Capricor Therapeutics USD 29.16M 2.87M Dec/2025
Cara Therapeutics USD 7.05M 1.11M Mar/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
Grifols EUR 1.99B 217.4M Dec/2025
Immunic USD 23.33M 2.67M Dec/2025
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
TherapeuticsMD USD 1.41M 50K Jun/2024